Head-to-head · Cost-Efficiency Index
PlushCare vs Teleios Health
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
PlushCare
Patients who want a real board-certified physician managing GLP-1s alongside general primary care, and are prepared to navigate insurance or a manufacturer cash-pay program rather than a single flat price.
Visit PlushCareTeleios Health
Shoppers comfortable calling or messaging before committing, since public pricing detail is minimal.
Visit Teleios HealthThe verdict
PlushCare and Teleios Health tie on the Cost-Efficiency Index at 65/100, so neither wins outright on the numbers. For most shoppers we'd start with PlushCare (ranked #166, a hair above #170) — Patients who want a real board-certified physician managing GLP-1s alongside general primary care, and are prepared to navigate insurance or a manufacturer cash-pay program rather than a single flat price. But Teleios Health is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs PlushCare.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | PlushCare | Teleios Health |
|---|---|---|
| Cost-Efficiency Index | 65/100 | 65/100 |
| Semaglutide / mo | $199/mo (0.25 mg dose, plus a separate fee, brand-name) | $99/mo (all doses, compounded) |
| Tirzepatide / mo | $399/mo (5 mg dose, plus a separate fee, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $2,388 | $1,188 |
| Tirzepatide / yr (modeled) | $4,788 | — |
| Coverage | All 50 states | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #166 | #170 |
PlushCare
65/100Where the value is
- Board-certified physicians (not NP-only) available in all 50 states for general virtual primary care
- Publishes an unusually granular compounded-tirzepatide dose ladder ($399/$599/$749 by vial count) instead of a vague single 'starting at' figure
- Brand Wegovy via NovoCare's manufacturer program can beat most compounded prices ($199-399/mo) when the promotion is genuinely still active
The tradeoffs
- Compounded tirzepatide and semaglutide are each only available in about 39 states plus DC, narrower than PlushCare's general 50-state telehealth business
- A $19.99/mo membership and, for uninsured patients, a $129 visit fee sit on top of every medication price and are easy to miss from the headline drug price alone
Teleios Health
65/100Where the value is
- Advertises a low $99/mo headline starting price, undercutting most compounded-GLP-1 competitors on paper
- Explicitly brands itself as 'physician-led,' setting an expectation of clinician oversight
- Discloses the standard compounded-medication FDA disclaimer up front rather than burying it
The tradeoffs
- No dose amount, drug, or inclusion breakdown is published for the $99/mo figure
- No visit fee, membership fee, or shipping fee disclosure could be found anywhere on the site
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.